Table 1. In vitro profile of YLT192 against a panel of 29 kinases. The assays were performed in two independent experiments. Data are means ± SD.

Kinase	inhibition rate at 1 μM (%)
VEGFR2	93 ± 3
Flt3	−6 ± 2
PDGFRα	5 ± 3
PDGFRβ	7 ± 8
cKit	6 ± 3
FGFR1	21 ± 3
FGFR2	19 ± 4
FGFR3	4 ± 6
Plk1	1 ± 3
Aurora-A	−1 ± 4
Aurora-B	23 ± 5
Ret	23 ± 3
Axl	−7 ± 7
Met	−2 ± 6
PKA	−10 ± 4
Fms	35 ± 11
CDK2/cyclinE	−9 ± 3
IR	3 ± 3
CDK6/cyclinD3	0 ± 4
EGFR	1 ± 6
PI3K	0 ± 2
IKKβ	2 ± 6
JNK3	3 ± 5
mTOR	0 ± 6
ALK	−4 ± 3
LCK	3 ± 6
GSK3β	4 ± 6
JAK3	−7 ± 4
c-RAF	3 ± 3